Stevanato Group (NYSE:STVN) Shares Gap Up – Time to Buy?

Stevanato Group S.p.A. (NYSE:STVN)’s share price gapped up prior to trading on Friday . The stock had previously closed at €18.51, but opened at €19.29. Stevanato Group shares last traded at €19.05, with a volume of 122,876 shares.

Wall Street Analyst Weigh In

Several research firms recently weighed in on STVN. KeyCorp dropped their price objective on shares of Stevanato Group from $37.00 to $32.00 and set an “overweight” rating on the stock in a research note on Thursday, March 5th. Wolfe Research initiated coverage on Stevanato Group in a report on Tuesday. They set an “outperform” rating and a $21.00 target price for the company. Citigroup cut their price target on Stevanato Group from $32.00 to $26.00 and set a “buy” rating on the stock in a report on Thursday, March 5th. Wall Street Zen downgraded Stevanato Group from a “buy” rating to a “hold” rating in a research note on Saturday, February 14th. Finally, Weiss Ratings cut Stevanato Group from a “hold (c-)” rating to a “sell (d+)” rating in a research note on Wednesday, March 11th. One equities research analyst has rated the stock with a Strong Buy rating, three have given a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy”.

Stevanato Group Trading Up 1.5%

The company has a debt-to-equity ratio of 0.21, a quick ratio of 1.11 and a current ratio of 1.63. The firm has a market capitalization of $5.69 billion, a P/E ratio of 32.06, a price-to-earnings-growth ratio of 1.71 and a beta of 0.78. The firm has a 50 day moving average price of €16.32 and a two-hundred day moving average price of €17.79.

Stevanato Group (NYSE:STVN) last announced its earnings results on Friday, May 8th. The company reported €0.11 EPS for the quarter, missing the consensus estimate of €0.12 by (€0.01). Stevanato Group had a return on equity of 10.27% and a net margin of 11.76%.The firm had revenue of €273.57 million during the quarter. During the same period last year, the firm posted $0.10 EPS. Stevanato Group’s revenue for the quarter was up 6.6% on a year-over-year basis. On average, equities research analysts expect that Stevanato Group S.p.A. will post 0.68 EPS for the current fiscal year.

Stevanato Group Cuts Dividend

The business also recently disclosed an annual dividend, which will be paid on Wednesday, July 29th. Investors of record on Thursday, June 11th will be given a dividend of $0.054 per share. The ex-dividend date of this dividend is Thursday, June 11th. This represents a yield of 29.0%.

Institutional Investors Weigh In On Stevanato Group

A number of institutional investors have recently modified their holdings of STVN. GW&K Investment Management LLC increased its stake in shares of Stevanato Group by 76.2% in the fourth quarter. GW&K Investment Management LLC now owns 2,440 shares of the company’s stock worth $49,000 after acquiring an additional 1,055 shares during the last quarter. Fifth Third Bancorp grew its stake in Stevanato Group by 22.6% in the first quarter. Fifth Third Bancorp now owns 4,196 shares of the company’s stock valued at $58,000 after purchasing an additional 773 shares in the last quarter. State of Wyoming increased its position in Stevanato Group by 39,216.7% in the 2nd quarter. State of Wyoming now owns 2,359 shares of the company’s stock worth $58,000 after purchasing an additional 2,353 shares during the last quarter. Quantbot Technologies LP purchased a new stake in shares of Stevanato Group during the 3rd quarter worth about $68,000. Finally, Tower Research Capital LLC TRC lifted its holdings in shares of Stevanato Group by 1,268.7% during the 2nd quarter. Tower Research Capital LLC TRC now owns 4,585 shares of the company’s stock valued at $112,000 after buying an additional 4,250 shares during the last quarter.

Stevanato Group Company Profile

Stevanato Group is a global provider of primary packaging solutions and related services for the pharmaceutical and biotech industries. The company specializes in the design, development and manufacturing of glass drug containers such as vials, cartridges and pre-fillable syringes, as well as advanced inspection systems and assembly equipment. Its integrated offerings cover the entire packaging supply chain, from component production to bespoke filling lines and serialization technology.

In addition to its core glass business, Stevanato Group delivers engineering services and process validation support to pharmaceutical customers.